Cell and gene therapy companies are the beneficiaries of positive changes along the regulatory path that the U.S. FDA is paving for them, according to a panel of executives who spoke at the BioFuture 2024 conference in New York. The agency is trying to set up cell and gene companies for success and that’s a very different agency than what it was years ago, said Paul Bresge, CEO of Ray Therapeutics Inc. Read More
Avacta Life Sciences (Avacta Group plc) presented preclinical data on AVA-6103, a second-generation Precision peptide-drug conjugate, being developed for the potential treatment of cancer. AVA-6103 was developed using the company’s proprietary Precision technology incorporating a dipeptide specifically cleaved by fibroblast activation protein α (FAPα) leading to tumor-specific delivery of exatecan directly into the tumor cells. Read More
Tevogen Bio Inc. has begun preclinical efforts for TVGN-920, its first oncology product. The company is leveraging Microsoft’s artificial intelligence (AI) and cloud technologies to accelerate its target identification and preclinical processes in human papillomavirus (HPV). Read More
Iksuda Therapeutics Ltd. disclosed the design of a novel, effective and safe antibody-drug conjugate (ADC), IKS-012, for the potential treatment of folate receptor α (FRα)-positive cancers. Read More
Researchers from Qingdao University described the discovery and preclinical characterization of a novel series of tubulin polymerization inhibitors that led to the identification of [I] as the most potent compound. Read More
Crossbridge Bio Inc. has closed a $10 million seed financing to support its development of dual-payload antibody-drug conjugates (ADCs) for cancer. Read More
The University of Kentucky has prepared and tested mithramycin oxime derivatives reported to be useful for the treatment of cancer and neurological disorders. Read More
Scientists from Universitätsklinikum Heidelberg and affiliated organizations aimed to characterize a novel Drosophila model for Dent disease. Read More
Researchers from Eli Lilly & Co. presented the discovery and preclinical characterization of a novel protein tyrosine kinase 7 (PTK7)-targeting antibody-drug conjugate (ADC), LY-4175408, being developed for the treatment of cancer. Read More
Cogent Biosciences Inc. has identified compounds acting as HER2 (erbB2) (L755S mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Beijing Normal University presented data on fibroblast activation protein (FAP)-targeting agents containing a nitroimidazole moiety, [68Ga]/[177Lu]AAZTA-NI-FAPI-04, being developed for the potential imaging and treatment of cancer. Read More
Shanghai Yidi Biotechnology Co. Ltd. has patented dihydrothienopyrimidine compounds acting as phosphodiesterase PDE4B2 and/or PDE4D2 inhibitors reported to be useful for the treatment of autoimmune, metabolic diseases, neurological and inflammatory disorders. Read More
Nanjing Zaiming Pharmaceutical Co. Ltd. has described proteolysis targeting chimera (PROTACs) compounds comprising of E3 ubiquitin ligase cereblon (CRBN)-binding moiety coupled to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety through a linker reported to be useful for the treatment of cancer. Read More
Scientists from the University of Wisconsin-Madison have reported the discovery of novel carbonic anhydrase IX (CAIX) radioligands for molecular imaging in clear cell renal cell carcinoma (ccRCC). Read More
